[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][=C][Branch2][=Branch1][=Branch1][C][=Branch2][Ring1][C][=C][C][=Branch1][Ring2][=N][Ring1][=Branch1][C][O][P][=Branch1][C][=O][Branch1][C][O][O][C][N][Branch2][Ring2][=Branch1][C][C][N][Branch2][Ring1][#Branch2][C][C][=C][C][=Branch1][#Branch2][=N][C][=Branch1][Branch1][=C][Ring1][=Branch1][O][C][C][O][P][=Branch1][C][=O][Branch1][C][O][O][C][C][=Branch1][C][=O][O-1][C][C][=Branch1][C][=O][O-1][O].[Mn+2]"}, {"from": "gpt", "value": "The molecule is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas. This drug is made up of paramagnetic manganese (II) ions combined with the chelating agent fodipir (dipyridoxyl diphosphate, DPDP). Manganese absorption into the tissues that makes the normal tissue appear brighter in MRI is limited in abnormal or cancerous tissue. Enhanced contrast by mangafodipir improves visualization and detection of lesions of the liver formed from metastatic disease or hepatocellular carcinomas. The contrast agent is present as mangafodipir trisodium marketed under the name Teslascan. Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012."}]